Literature DB >> 21531172

Steroid up-regulation of FKBP51 and its role in hormone signaling.

Tiina Jääskeläinen1, Harri Makkonen, Jorma J Palvimo.   

Abstract

FK506 binding protein 51 (FKBP51, FKBP5) functions as a co-chaperone for androgen, glucocorticoid, mineralocorticoid and progesterone receptors. The FKBP51 can act as an important determinant of the responses to steroids, especially to glucocorticoids in stress and mood disorders and androgens in prostate cancer, raising medical and pharmacological interests in the protein and its gene. Recent studies have revealed the molecular mechanisms by which the androgens and the glucocorticoids via their nuclear receptors elicit the robust up-regulation of the FKBP51 gene. Several polymorphisms in the FKBP51 gene have been associated with the mood disorders and differences in glucocorticoid sensitivity. The polymorphisms may contribute to the steroid up-regulation of the FKBP51 and thus influence the regulatory loops in steroid signaling.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21531172     DOI: 10.1016/j.coph.2011.04.006

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  57 in total

1.  Glucocorticoid sensitizers Bag1 and Ppid are regulated by adolescent stress in a sex-dependent manner.

Authors:  Chase H Bourke; Madiha Q Raees; Sanjana Malviya; Cory A Bradburn; Elisabeth B Binder; Gretchen N Neigh
Journal:  Psychoneuroendocrinology       Date:  2012-05-29       Impact factor: 4.905

Review 2.  Gene-Stress-Epigenetic Regulation of FKBP5: Clinical and Translational Implications.

Authors:  Anthony S Zannas; Tobias Wiechmann; Nils C Gassen; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2015-08-13       Impact factor: 7.853

Review 3.  Glucocorticoid sensitivity in health and disease.

Authors:  Rogier A Quax; Laura Manenschijn; Jan W Koper; Johanna M Hazes; Steven W J Lamberts; Elisabeth F C van Rossum; Richard A Feelders
Journal:  Nat Rev Endocrinol       Date:  2013-10-01       Impact factor: 43.330

4.  USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling.

Authors:  Kuntian Luo; Yunhui Li; Yujiao Yin; Lei Li; Chenming Wu; Yuping Chen; Somaira Nowsheen; Qi Hu; Lizhi Zhang; Zhenkun Lou; Jian Yuan
Journal:  EMBO J       Date:  2017-03-31       Impact factor: 11.598

Review 5.  The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside.

Authors:  Jieping Hu; Qingke Chen
Journal:  Int Urol Nephrol       Date:  2016-12-16       Impact factor: 2.370

Review 6.  Stress-induced sex differences: adaptations mediated by the glucocorticoid receptor.

Authors:  Chase H Bourke; Constance S Harrell; Gretchen N Neigh
Journal:  Horm Behav       Date:  2012-03-03       Impact factor: 3.587

Review 7.  Genomic and epigenomic mechanisms of glucocorticoids in the brain.

Authors:  Jason D Gray; Joshua F Kogan; Jordan Marrocco; Bruce S McEwen
Journal:  Nat Rev Endocrinol       Date:  2017-09-01       Impact factor: 43.330

8.  A comparison of prostate cancer cell transcriptomes in 2D monoculture vs 3D xenografts identify consistent gene expression alterations associated with tumor microenvironments.

Authors:  Lauren Brady; Rui M Gil da Costa; Ilsa M Coleman; Clinton K Matson; Michael C Risk; Roger T Coleman; Peter S Nelson
Journal:  Prostate       Date:  2020-02-18       Impact factor: 4.104

Review 9.  The role of FKBP5 in mood disorders: action of FKBP5 on steroid hormone receptors leads to questions about its evolutionary importance.

Authors:  John C O'Leary; Bo Zhang; John Koren; Laura Blair; Chad A Dickey
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

10.  PKCδ Mediates Mineralocorticoid Receptor Activation by Angiotensin II to Modulate Smooth Muscle Cell Function.

Authors:  Qing Lu; Ana P Davel; Adam P McGraw; Sitara P Rao; Brenna G Newfell; Iris Z Jaffe
Journal:  Endocrinology       Date:  2019-09-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.